Systemic inflammation and risk of multiple sclerosis – A presymptomatic case-control study

Multiple Sclerosis Journal �C Experimental, Translational and Clinical

article

Viktor Grut¹  Martin Biström¹  Jonatan Salzer¹  Pernilla Stridh²  Anna Lindam⁴  Lucia Alonso-Magdalena⁵  Oluf Andersen⁶  Daniel Jons⁶  Martin Gunnarsson⁷  Magnus Vrethem⁸  Johan Hultdin⁹  Peter Sundström¹ 

[1] Department of Clinical Science, Neurosciences, Umeå University;Department of Clinical Neuroscience, Karolinska Institutet;Center for Molecular Medicine, Karolinska University Hospital;Department of Public Health and Clinical Medicine, Unit of Research, Education and Development Östersund Hospital, Umeå University;Department of Neurology, Skåne University Hospital and Department of Clinical Sciences, Neurology, Lund University;Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg;Department of Neurology, Faculty of Medicine and Health, Örebro University;Department of Neurology and Department of Biomedical and Clinical Sciences ,(BKV), Linköping University;Department of Medical Biosciences, Clinical Chemistry, Umeå University

关键词: Case-control studies;    C-reactive protein;    systemic inflammation;    multiple sclerosis;   

DOI  :  10.1177/20552173221139768

来源: Sage Journals

【 摘 要 】

Background: C-reactive protein (CRP) is a marker of systemic inflammation. Increased levels of CRP inyoung persons have been suggested to decrease the risk of multiple sclerosis (MS).Objectives: To assess CRP as a risk factor for MS.Methods: Levels of CRP were measured with a high-sensitive immunoassay in biobank samples from 837individuals who later developed MS and 984 matched controls. The risk of developing MS was analysedby conditional logistic regression on z-scored CRP values.Results: Levels of CRP were not associated with MS risk.Conclusions: We found no association between CRP levels and risk of MS development.

【 授权许可】

Unknown